S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

89bio Stock Price, News & Analysis (NASDAQ:ETNB)

$9.86
-0.09 (-0.90%)
(As of 12/8/2023 ET)
Compare
Today's Range
$9.60
$10.01
50-Day Range
$6.66
$16.03
52-Week Range
$6.57
$22.93
Volume
1.70 million shs
Average Volume
1.58 million shs
Market Capitalization
$745.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.89

89bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
233.6% Upside
$32.89 Price Target
Short Interest
Bearish
7.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of 89bio in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.09) to ($2.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

841st out of 954 stocks

Pharmaceutical Preparations Industry

322nd out of 362 stocks


ETNB stock logo

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

ETNB Stock News Headlines

Buy Rating Affirmed for 89bio Amid Promising NASH Drug Developments
Buy Rating Affirmed for 89bio Amid Promising NASH Drug Developments
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
89bio's (ETNB) "Buy" Rating Reaffirmed at HC Wainwright
89bio (NASDAQ:ETNB) Receives "Buy" Rating from HC Wainwright
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
89bio's Low Price Presents An Opportunity
89bio: Risk And Reward Balance In NASH Therapeutics
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/08/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.89
High Stock Price Target
$50.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+233.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-102,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
72,311,000
Market Cap
$745.80 million
Optionable
Not Optionable
Beta
0.89
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 57)
    CEO & Director
    Comp: $990.52k
  • Mr. Quoc Le-Nguyen (Age 55)
    Chief Technical Operations Officer & Head of Quality
    Comp: $654.44k
  • Dr. Harry Mansbach M.D. (Age 58)
    Chief Medical Officer
    Comp: $691.87k
  • Mr. Ryan Stephen Martins (Age 45)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan (Age 57)
    Senior Vice President of Finance & Principal Accounting Officer
  • Ms. Melissa Abel
    Senior Vice President of Commercial Strategy & Communications
  • Ms. Amanda Kurihara
    Vice President of People & Culture
  • Ms. Yun Bai
    VP & Head of CMC
  • Mr. Paul Shin
    Senior Vice President of R&D Operations
  • Mr. Michael Baldwin
    VP & Head of Quality














ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price target for 2024?

6 brokers have issued 12-month target prices for 89bio's stock. Their ETNB share price targets range from $24.00 to $50.00. On average, they expect the company's share price to reach $32.89 in the next twelve months. This suggests a possible upside of 233.6% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2023?

89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has decreased by 22.5% and is now trading at $9.86.
View the best growth stocks for 2023 here
.

Are investors shorting 89bio?

89bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 6,040,000 shares, an increase of 11.2% from the October 31st total of 5,430,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 3.9 days.
View 89bio's Short Interest
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.08. The firm earned $1 million during the quarter, compared to analyst estimates of $0.38 million. 89bio's revenue for the quarter was up .0% on a year-over-year basis.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (2.82%), Adage Capital Partners GP L.L.C. (2.25%), Braidwell LP (2.11%), Westfield Capital Management Co. LP (1.74%), Laurion Capital Management LP (1.59%) and Eagle Asset Management Inc. (0.94%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -